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About two thirds of all human breast cancer cases are estrogen receptor positive. The drug of ﬁrst choice for these patients is
tamoxifen. However, about half of the recurrences after removal of the primary tumor are or become resistant to this drug.
While many mechanisms have been identiﬁed for tamoxifen resistance in the lab, at present only a few have been translated to
the clinic. This paper highlights the role in tamoxifen resistance of phosphorylation by diﬀerent kinases on diﬀerent sites of the
estrogen receptor. We will discuss the molecular pathways and kinases that are involved in phosphorylation of ERα and how these
aﬀect tamoxifen resistance. Finally, we will elaborate on the clinical translation of these observations and the possibility to predict
tamoxifen responses in patient tumor samples before treatment onset. The ﬁndings made originally on the bench may translate
into a better and personalized treatment of breast cancer patients using an old and safe anticancer drug: tamoxifen.
1.Introduction
Worldwide, some 1.5 million women are diagnosed with
breast cancer annually. Approximately, 70% of human
breast cancer expresses estrogen receptor alpha (ERα). These
tumors are eligible to endocrine therapy. Over the last 30
years, tamoxifen has been the antiestrogen of ﬁrst choice.
However, about half of the recurrences in ER-positive breast
cancer do not respond to tamoxifen, which is due to either
acquired resistance or to intrinsic insensitivity to tamoxifen
[1, 2]. From experimental studies, many diﬀerent mecha-
nisms have been suggested to explain resistance, including
activation of kinase pathways or inactivation of pRb, that
render the tumor cell independent of the ER pathway for its
proliferation [2]. However, with exception of cErbB2 (neu)
overexpression, which mostly, but not exclusively occurs in
ERα-negative breast cancer [3, 4], currently none of the
resistance mechanisms identiﬁed have been translated into
clinical implementation.
It is evident that multiple factors are involved in tamox-
ifen resistance. Therefore, they should be examined together
as an integrated set of predictive markers for diagnosis
of individual patients. Not only the number of clinically
relevant indicators for tamoxifen resistance is unknown, but
also the proportion in which a particular marker contributes
to resistance in patients is unclear. The relative contribution
of these factors should be deﬁned and potentially integrated
into a combined set of predictive markers for tamoxifen
responses of individual patients.
Tamoxifen stimulates the growth of osteoblasts, while it
inhibits ERα-positive breast tumor cells. These two opposing
eﬀects of tamoxifen on cell growth can be explained by
the fact that tamoxifen is a partial antagonist, acting as an
agonistunderparticularconditions[5].Tamoxifenresistance
is usually due to a direct eﬀect on ERα;t a m o x i f e nm a y
acquire agonistic properties for transactivation of ERα [6].
Therefore, a molecular understanding of the underlying
mechanism of tamoxifen resistance could result in markers
that specify how patients will respond to endocrine therapy.
The potential translation of these markers into clinical
evaluation has to be examined with historical material and
ultimately in a prospective study. Identiﬁcation of markers
predictingtheantibreastcancerresponsetotamoxifenwould
have major clinical implications. Currently, the clinical
beneﬁtoftamoxifenissimilartothatofaromataseinhibitors,
although the side eﬀects of the drugs markedly diﬀer.2 International Journal of Breast Cancer
Ultimately, by ﬁnding predictive markers, responsiveness to
tamoxifen can be deﬁned before treatment and patients will
only receive tamoxifen if they are likely to beneﬁt from
it. And in case of resistance, patients may still respond to
another treatment modality, such as aromatase inhibitors or
the full antiestrogen antagonist, like fulvestrant, which may
still be beneﬁcial [5].
The estrogen receptor superfamily consists of two
homologous nuclear receptors: ERα and ERβ.E R β is
encoded by a diﬀerent gene, and the two receptors exhibit
diﬀerent transcriptional activities and functions in breast
cancer [7]. Because the phosphorylation of ERβ and a
potential role in tamoxifen resistance have not been well
characterised, we will not discuss this estrogen receptor
subtype.
In this chapter, we focus on phosphomodiﬁcations of
ERα in tumor cells that, by themselves, do not aﬀect the
female hormone estradiol (E2) dependency of the tumor
cells for proliferation, but could aﬀect the response to
tamoxifen. We will address the following questions: which
phosphorylation sites are identiﬁed on ERα? How do these
sites become phosphorylated? Which sites are associated
with tamoxifen resistance? How does tamoxifen sensitivity
become aﬀected without any eﬀe c to nE 2d e p e n d e n c y ?
Which molecular pathways upstream or downstream of the
phosphorylated ER are involved in this form of tamoxifen
resistance? Which clinical data are in support of tamoxifen
resistance due to phosphorylated ERα?
2. Effects of Phosphorylation on
the Structure of ERα Which Are Relevant for
Tamoxifen Resistance
Phosphorylation of the estrogen receptor may change the 3-
dimensional structure of the protein. Unfortunately, thus far
no full-length ERα has been crystallised. This complicates
characterisation of structural changes upon ligand binding
or posttranslational modiﬁcations, such as phosphorylation.
Furthermore, a conformational change due to phosphory-
lation could have consequences for the action of estrogens
and antiestrogens. X-ray crystallography studies have thus
far been performed on the ligand binding domain (LBD)
of ERα. Estradiol binds to amino acids Glu353 from helix
3(H3), Arg394 from H5, and to His524 from H11 in the
L B Do fE R[ 8], whereas D351 in the LBD is critical for the
interaction with the antiestrogen. Speciﬁc mutation of D351
into D351Y resulted in a receptor that shows an estrogenic,
instead of an antiestrogenic, response to tamoxifen [9].
Coactivators have a common signature motif, LXXLL,
with which they can interact with ERα in a hormone-
dependent manner [10]. Whereas in a nonligand-bound
state helix 12 is highly mobile, upon binding of an agonist
it takes a more ﬁxed position, stabilising the conformation of
ERα. Helix 12 forms a charge clamp with helix 3, creating
a hydrophobic groove to which a coactivator can bind. In
contrast, crystallography shows that, when an antagonist,
such as tamoxifen, binds to the LBD, helix 12 itself occupies
the coactivator binding site, rendering ERα inactive [11–13].
Structural changes of ER can inﬂuence coregulator binding
and hence potentially the response to ligands.
Besides binding to the LBD in the AF-2 domain,
coactivators also bind to the AF-1 domain of ERα,i na
ligand-independent manner. Phosphorylation of sites within
or outside the AF-1 region may aﬀect the AF-1-dependent
binding of cofactors as well.
Phosphorylation of particular sites, especially of S118
and S305, aﬀects the binding of coactivators in the presence
of tamoxifen [14]. In case of S305, this is due to an
altered conformation of ERα, which can be measured by
ﬂuorescence resonance energy transfer (FRET) [15]. In the
presence of tamoxifen, S305 phosphorylation changes the
orientation between ERα and coactivator SRC-1 [14]. This
altered orientation renders ERα transcriptionally active in
the presence of tamoxifen. An altered conformation of ERα
due to phosphorylation of S305 resulted in a tamoxifen-
resistant phenotype of ERα, not only measured by FRET,
but also by biological assays [6, 16]. Not only tamoxifen
but also arzoxifene is converted from an antagonist into
an agonist after the S305 phosphorylation-induced con-
formational arrest of ERα [16]. These ﬁndings strongly
suggest that subtle changes in the conformation of ERα upon
binding to antiestrogens are at the basis of resistance to
antiestrogens.Thisprovidestheframeworktoconsiderarole
for phosphorylation of ERα in resistance to tamoxifen.
3.ERα Phosphorylation Sites witha Putative
Role inTamoxifen Resistance
Several kinase pathways have been associated with tamoxifen
resistance,includingactivationoftheproteinkinaseA(PKA)
[17], mitogen-activated protein kinase (MAPK) [18]a n d
p21-activated kinase-1 (PAK-1) signaling pathways [19].
These kinases induce phosphorylation of ERα or of its
coregulators. This paper focuses on the phosphorylation
sites on ERα that could contribute to an altered response
to tamoxifen and on which kinase pathways and upstream
activators are involved. A summary of the putative phospho-
rylation sites in ERα is presented in Figure 1 and Table 1.
They are discussed separately below.
3.1. S102/S104/S106. Serine residues S102, S104, and S106
at the N-terminal AF-1 region of ERα are phosphorylated
by glycogen synthase kinase-3 (GSK-3) and by extracellular
signal-regulated kinases 1 and 2 (ERK1/2) and mitogen-
activated protein kinase (MAPK) (=MEK1/2) pathways.
These modiﬁcations lead to ligand-independent transcrip-
tion of ERα and to an agonistic activity of tamoxifen
[22, 23]. S102, a phosphorylation site discovered by mass
spectrometry, requires concurrent phosphorylation of S104
[20]. ERα phosphorylation by GSK-3, which also targets
S118, stabilizes ERα without ligand and modulates ERα
transcriptional activity upon ligand binding. S104 and
S106 can also be phosphorylated by the CDK2/cyclinA
complex [24]. Cyclin A has been reported as a predictive
marker for tamoxifen resistance in breast cancer patients
[51].International Journal of Breast Cancer 3
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Figure 1: ERα phosphorylation involved in tamoxifen response. From left to right: AF-1 domain, DNA-binding domain (DBD), hinge
region, AF-2 domain, and F domain containing helix 12.
Table 1: Putative ERα phosphosites, the kinases that target them, and the eﬀect on tamoxifen response.
Phosphosite Kinases Tamoxifen Reference
S46/47 PKC [20]
Y52 c-Abl [21]
S102/4/6 GSK-3, ERK1/2 MAPK, CDK2 Resistance [20, 22–24]
S118 CDK2, ERK1/2 MAPK, RAS/MAPK, GSK-3, CDK7, IKKα, mTOR/p70S6K Dual eﬀect [18, 25–34]
S154 [20]
S167 ERK1/2 MAPK, p90RSK, CK2, Akt, mTOR/p70S6K Sensitivity [25, 30, 32, 34–39]
S212 [20]
Y219 c-Abl [21]
S236 PKA [17, 32]
S282 CK2 Sensitivity [20, 40, 41]
S294 [20, 40]
S305 PKA, PAK1? Resistance [15, 19, 32, 42–47]
T311 RAS/MAPK [21, 40]
Y537 Src Y kinases Dual eﬀect [25, 32, 48–50]
S554 [20]
S559 CK2 [20, 41]
3.2. S118. Serine 118 is one of the most reported phospho-
rylation sites of ERα. It is targeted by a number of kinase
pathways:MAPK,GSK-3,IKKα,CDK7,andmTOR/p70S6K.
S118 phosphorylation by MAPK increases binding of coacti-
vator SRC3 [25] and renders ERα hypersensitive to estradiol
[26]. Phosphorylated S118 decreases ERα aﬃnity for tamox-
ifen and reduces binding to DNA, when ERα is tamoxifen
bound [25]. In a tamoxifen-resistant cell line obtained by
selection after prolonged exposure to tamoxifen, MAPK
activity was found to be elevated and S118-P was increased
[26]. Upstream, the RAS/MAPK pathway can be activated
by IGF stimulation inducing phosphorylation of ERα S118
and resulting in ERα activation and enhanced response to
estradiol [18]. Estradiol and EGF can induce the ERK1/2
MAPK pathway, which also leads to S118 phosphorylation
of ERα [27]. Estrogen-dependent phosphorylation of S118-
P can occur not only through the ERK1/2 MAPK pathway,
but also by IKKα [28] and CDK7, a subunit of transcription
factor II H [29].
In MCF7 cells, the receptor tyrosine kinase RET
mediates ERα phosphorylation at S118 and S167 via the
mTOR/p70S6K pathway [30]. Activation of RET leads
to estrogen-independent transcriptional activation of ER-
dependent genes and resistance to tamoxifen, strongly4 International Journal of Breast Cancer
suggesting that RET activity acts through the estrogen recep-
tor. This hypothesis is supported by a chromatin immuno-
precipitation (ChIP) study on ERα and S118 mutants
[52]. Phosphorylation of S118 inﬂuences the recruitment
of coregulators to ERα-regulated genes pS2, c-myc, and
cyclin D1 and aﬀects E2-induced gene expression. The
nonphosphorylatable S118A mutant has a greater impact
on genes regulated through nonclassical mechanisms, such
as ERα binding to fos/jun on an AP-1 promoter, than on
estrogen responsive elements (ERE).
TheclinicalrelevanceofS118phosphorylationintamox-
ifen resistance is still unresolved. On the one hand, S118-P
has been associated with a more diﬀerentiated phenotype,
good prognosis, and better response to tamoxifen [28],
which is supported by other studies (see [31], Wigerup et al.
unpublished data). Most importantly, these studies reported
that the S118 phosphorylation had no eﬀect on progression
of disease or survival without tamoxifen treatment [31],
thereby emphasizing that S118 phosphorylation is a clear
predictive marker for response to tamoxifen in these studies.
On the other hand, S118 phosphorylation was negatively
correlated with response to endocrine therapy in patients
in other studies [32–34]. Nontreated patients have a better
prognosis when they are positive for S118-P in these studies
[32, 33]. These results are not easily reconciled with the
previously mentioned studies (see [28, 31], Wigerup et
al. unpublished data). Besides diﬀerences in patient series
and tumor types, it is not clear which kinase activities
in the tumors are resulting in S118 phosphorylation. In
patients, both MAPK and RET expressions are associated
withpoor response toantihormonal therapy [53].Activation
of the ERK1/2 MAPK pathway apparently results in S118
phosphorylation, but it also induces a bypassing of the ER
pathway, thereby rendering tumors hormone-independent.
CDK7-mediated phosphorylation is indicative of an
active ERα. Whereas the MAPK mechanism may well be
responsible for a worse outcome of disease, irrespective of
tamoxifen treatment, the CDK7 mechanism would indicate
a proper functioning of ERα, being an adequate target for
tamoxifen treatment [33].
3.3. S167. Serine 167 is phosphorylated by Akt, p90RSK,
and mTOR/p70S6K. The latter kinase also phosphorylates
S118. Akt is induced by EGF and IGF [35], p90RSK only
by EGF stimulation [36]. EGFR overexpression induces
S167 phosphorylation, increases binding of ERα to DNA,
enhances the binding of coactivator SRC3 to ERα in the
presence of E2, and consequently enhances transcription.
Moreover, in vitro, S167-P reduces sensitivity to tamoxifen
[25, 32]. Other kinases that target S167 include ERK1/2
MAPK [32, 37] and, upon E2 binding of ERα,c a s e i n
kinase II (CK2) [38]. S167-P does not aﬀect ligand binding
[25].
TheclinicaldataofS167phosphorylationareconﬂicting.
In ERα-positive, tamoxifen-treated patients, activated AKT
(pAKT) is associated with high risk for relapse and decreased
overall survival [39], which would imply that S167-P is
associated with a worse disease outcome. However, it is
important to realise that Akt, like ERK1/2 MAPK, has many
other targets, which could well bypass the estrogen-receptor-
dependent signaling.
Notwithstanding, in a set of 75 primary breast carcino-
mas of patients with metastatic breast cancer who received
ﬁrst-line endocrine treatment after relapse, those staining
highforS167-Prelapsedlater.Themetastasesrespondedwell
to endocrine treatment and S167-P correlated with longer
survival after relapse. This implies that S167-P is a predictive
marker for a good response to endocrine therapy [34, 37].
3.4. S282. Serine 282 resides in the hinge region and, like
S167, can be phosphorylated by CK2. Estradiol increases
phosphorylation of S282, stabilizes ER, and induces tran-
scriptional activity [20]. In patients, low levels of S282 phos-
phorylation are associated with reduced overall survival in
ER-positive breast tumors from tamoxifen-treated patients,
suggesting that S282 phosphorylation can be predictive for
response to tamoxifen [40].
3.5. S305. Serine 305 resides at the C-terminus of the hinge
region that provides a centre of rotation to the total ERα.
The region around Ser305 is a multifunctional domain
that binds to many coregulatory proteins and is involved
in the regulation of activity and stability of ERα [42].
Phosphorylation of Ser 305 occurs by protein kinase A and
is associated with resistance to tamoxifen in patients (see
[43–45], Wigerup et al. unpublished data). This domain also
controls ERα ubiquitination and subsequent proteosomal
degradation of ERα, that is inﬂuenced by ligands [46]. Dif-
ferentligandscaninducediﬀerentconformationsofERαand
hence aﬀect accessibility to the hinge region for modifying
proteins, such as ubiquitin ligases. This implies that ligands
can be selective for speciﬁc posttranslational modiﬁcations.
Within the hinge region, lysines K302/303 are involved in
proteasomal degradation of ERα by fulvestrant and are
the targets of polyubiquitination. K302 and K303 are both
required for monoubiquitination by the BRCA1/BARD1
E3 ligase of E2- or tamoxifen-bound ERα [54]. K303 is
also target for acetylation (inhibiting ER activity) and for
methylation (stabilizing ER and increasing activity), whereas
S305 phosphorylation prevents acetylation of K303 [55],
thereby stimulating ER activity. The reverse is also true:
a K303R mutation is frequently found in breast cancer,
which prevents acetylation and increases phosphorylation of
Ser305 by PKA [56]. These ﬁndings indicate that the hinge
region is aﬀected by various posttranslational modiﬁcations
that aﬀect structure and functioning of ERα. Some of these
modiﬁcations and their cross-talk are shown in Figure 2.
Besides PKA, p21-associated kinase 1 (PAK1) has been
suggested as an upstream kinase involved in the phospho-
rylation of Ser305. PAK1 phosphorylation of ERα S305
can lead to a secondary event on S118, presumably due
to a conformational change of the estrogen receptor [15,
19]. PAK1 overexpression by itself is associated with resis-
tance to tamoxifen in vitro [19]a sw e l la si np a t i e n t s
[32, 44, 45, 47]. Notably, in an experimental tamoxifen-
resistant setting, tamoxifen induces PAK1, maintaining ERα
in the tamoxifen-insensitive state [19]. The evidence that
PAK1 phosphorylates S305 [19] was indirect and was notInternational Journal of Breast Cancer 5
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Figure 2: Posttranslational modiﬁcations in the ERα hinge region.
S305 phosphorylation prevents acetylation of K302/303. The nat-
ural K303R mutation blocks K302/303 acetylation and stimulates
S305 phosphorylation.
conﬁrmed by a direct inspection of the phosphorylation of
ERα Ser305 using speciﬁc antibodies or by the introduction
of a dominant-active PAK1 into breast cancer cells [44].
Moreover, overexpression of PAK1 was not correlated with
S305 phosphorylation in two diﬀerent studies on breast
cancer, indicating that these two events are independent (see
[44], Wigerup et al. unpublished data). PKA phosphorylates
S305, keeping ER in an active conformation when tamoxifen
is bound, which means that it mimics an estrogen-bound
ER [15]. This was not observed with overexpression of PAK1
[44].
Clinical studies show that tamoxifen resistance occurred
in endocrine-treated patients with detectable S305-P in the
primary human breast tumor [44]. Since S305 phospho-
rylation has no eﬀect on patients that were not endocrine
treated, this Ser305P markers appears to be a predictive
marker for treatment outcome and not for general disease
progression [43]. A combination of PAK-1, phosho-PKA,
a marker of activated PKA, and the phosphorylated S305
marker identiﬁed approximately 60–70% of all tamoxifen
resistant cases in breast cancer. This occurred in series
of breast cancer from premenopausal and postmenopausal
patients,inearlytoadvancedstagesofdisease,indicatingthat
the marker is independent of clinical stage of disease and of
the hormonal status of the patient (see [31, 43, 45], Wigerup
et al. unpublished data).
3.6. Y537. Tyrosine 537 is phosphorylated by the Src
family tyrosine kinases. Phosphorylation of this tyrosine
inhibits ER dimerisation and estrogen binding and reduces
transcriptional activity of ERα [48]. Tyr 537 is located
at the N-terminus of helix 12, and mutation of this Tyr
into a nonphosphorylatable alanine facilitates the rotation
of helix 12 into an active conformation of ERα in the
absence of any ligand [49]. Phosphorylation by activated
Src increases aﬃnity for E2 and decreases aﬃnity for
tamoxifen [25]. Nonphosphorylatable mutants show ligand-
independent transactivation, but this is inhibited by tamox-
ifen [32]. There is no apparent clinical evidence that Y537
phosphorylation inﬂuences tamoxifen response in patients.
Of note, a naturally, but rarely occurring, Y537 mutation
to asparagine (Y537N) in breast cancer metastasis con-
stitutively activates the estrogen receptor by a conforma-
tional change of helix 12, which may contribute to breast
cancer progression and resistance to endocrine treatment
[50].
4.Other ERα Phosphorylation Sites with
No (Known) Role inTamResistance
Several other phosphorylation sites of ERα have been found,
which have not been associated with tamoxifen, either since
tamoxifen was not included in the studies or because the
phosphosite has not been included in clinical studies on
tamoxifen resistance. These sites are brieﬂy discussed below.
4.1. S46/47. Ser-46/47 phosphorylation plays a role in
ligand-dependent activation of ERα. Mutation of Ser-46/47
or Ser-294 to alanine markedly reduced estradiol-dependent
reporter activation. S47 phosphorylation may inﬂuence
other posttranslational modiﬁcations of ERα.S 4 6i sa
putative recognition site for protein kinase C and seems
to hold a predominant eﬀect on transcriptional activity,
rendering S47 phosphorylation a “bystander” eﬀect [20].
4.2. Y52 and Y219. Tyrosine 52 and 219 are phosphorylated
by c-Abl, a Src-like nonreceptor tyrosine kinase. Y219
phosphorylation aﬀects ER dimerization and DNA binding.
This results in enhanced ERα transcriptional activity, both
in absence and presence of estradiol. Stabilisation of ERα
through c-Abl ultimately leads to proliferation and invasion
of breast tumor cells [21].
4.3. S154, S212, S294, and S554. Serine 154, 212, 294,
and 554 are putative ERα phosphorylation sites discovered
by mass spectrometry on phosphopeptides [20]. In vitro,
an alanine mutation of S294 reduces estradiol-dependent
transcription [20], suggesting that S294 phosphorylation is
needed for a functional ER. Furthermore, S294 phosphory-
lation has been detected by immunohistochemistry (IHC) in
human breast carcinoma but no signiﬁcant eﬀect of S294-
P on tamoxifen response in terms of recurrence or overall
survival has been observed [40]. The biological relevance of
the other three serines remains to be tested.
4.4. S236. Serine 236 is located in the DNA binding domain
(DBD). It is phosphorylated by PKA, upon which ER
dimerisation and DNA binding in the absence of ligands
are lost, rendering ER transcriptionally inactive [32], but
both estradiol and tamoxifen can overcome this inhibition
[17]. This would imply that S236-P in itself has no eﬀect on
tamoxifen sensitivity.6 International Journal of Breast Cancer
4.5. T311. Threonine 311 is the only known threonine
phosphorylation site on ERα. An active RAS/MAPK pathway
stimulates ERα phosphorylation at Thr-311 [21]. Phospho-
rylation of T311 can be detected by immunohistochemistry,
but thus far has not been signiﬁcantly associated with altered
tamoxifen sensitivity in breast cancer patients [40].
4.6. S559. Serine 559, like Y537, resides in the F domain
of the estrogen receptor, in helix 12. This is of particu-
lar interest, because the position of helix 12 determines
interaction with coactivators and corepressors and regulates
response to (ant)agonists. Therefore, S559 phosphorylation
can probably inﬂuence ER binding to coregulators, such
as SRC-1, by changing the position of helix 12 and as a
consequence the response to ER ligands. S559 is targeted
by CK2 [20]. Phosphorylation inhibits ligand-independent
activation of ERα.E R α is phosphorylated at S559 in human
breast carcinoma biopsies [41].
5. MainPoints,Sideissues,and
InterrelatedAffairs
We presented, thus far, the eﬀects of phosphorylation of
relevant sites in ERα as single events. Of course, reality is
more complex and modiﬁcations not only occur on ERα
itself, but also take place on the associated cofactors and on
targets outside the ERα signaling pathways that could have
an eﬀect on ERα-mediated signaling. Three examples below
illustrate this point.
(a) Phosphorylation of CARM1, an arginine meth-
yltransferase, by PKA [57]. Phosphorylation of
CARM1 by PKA enhances its interaction with S448
in the LBD of ERα and creates a novel, more ﬁrm
platformforbindingofothercofactors.Thenetresult
is tamoxifen resistance by the buildup of a PKA-
speciﬁc coactivator complex. Because the arginine
methyltransferase CARM1 is involved in methylation
ofhistonesH3andH4thatiscrucialfortranscription
tooccur,theERα-phosphoCARM1complexprovides
a speciﬁc regulatory unit for transcription. Still,
additionaleventsareneededfortamoxifenresistance,
among which possibly the phosphorylation of ERα
S305 by PKA.
(b) PAK1 phosphorylates an alternate, but in breast can-
cer frequently present, isoform of the SRC3 ster-
oid-receptor cofactor (SRC3-3δ4), allowing it to
bridge between EGF-R and FAK1 (focal adhesion
kinase 1) and thereby activating ERK1/2 MAPK [58].
Activation of this pathway possibly renders breast
tumor cells tamoxifen resistant. This provides a novel
turn to the role of PAK1 overexpression in breast
cancer.
(c) The selective activity of SRC-3 depends on speciﬁc
phosphorylation of SRC3 [59]. SRC3 has six speciﬁc
phosphorylation sites targeted by multiple kinases.
These phosphorylated sites determine the optimal
interaction with other transcription factors and are
required for diﬀerent physiological functions.
Thesethreeexamplesdemonstratethatthereisacomplex
interrelated network of regulatory circuits inﬂuencing ER
transcriptional activity and that, by modiﬁcation of one
circuit, other circuits are aﬀected. They also indicate that one
particular mode of modiﬁcation can have multiple eﬀects.
Most ofthe studies haveaddressed onlyone signiﬁcant mode
of action, but it is evident that many factors can play a role in
the resistance to endocrine treatment.
6.DownstreamSignaling/Gene
Expression/Pathways
How does phosphorylation of ERa aﬀect resistance to
tamoxifen? The estrogen receptor is a nuclear receptor,
which binds to speciﬁc sequences in the DNA and regulates
the expression of ER-dependent genes. Phosphorylation of
ERα can aﬀect DNA binding, for example, by inhibiting
dimerization of the receptor, and can inﬂuence ERα activity
by changing the binding to coactivators or the orientation
of components of the transcription factor complex. Which
genes are then aﬀected? In the classical way, an estradiol-
bound estrogen receptor dimerizes, binds to an estrogen
responsive element (ERE), and transcribes the gene that lies
within its proximity. The estrogen receptor can also regulate
transcription of genes in an indirect manner, by binding
to other transcription factors: AP-1, SP-1 [60], or activated
NFkB [61]. When these interactions occur, transcription of
the AP-1-, SP-1-, or NFkB-dependent genes becomes also
dependent on ERα. When tamoxifen is bound to ERα, the
classical estrogen responsive genes are not expressed but
tamoxifen-bound ERα has its own, diﬀerent transcriptome,
most likely generated through the nonclassical pathway [62,
63].
Diﬀerent kinase pathways can be activated chemically in
cells by adding growth factors (EGF or IGF) or cAMP, which
induces PKA. This approach was used in a gene expression
study on MCF7 breast cancer cells [64]. Kinases were
activated, and gene expression proﬁles were compared in
the presence or absence of tamoxifen. Tamoxifen treatment
resulted in diﬀerential gene expression with either growth
factor stimulation or PKA activation. Which of these genes is
essential for tamoxifen resistance remains a crucial question.
A more complete, but also more complex, picture arises
frommicroarrayanalysesperformedintumorsoftamoxifen-
treated ERα-positive breast cancer patients. Frasor et al.
described a set of genes associated with disease recurrence, a
subset of which is associated with treatment with tamoxifen
[63]. Loi et al. applied gene expression proﬁling in a similar
way. They developed a gene classiﬁer to predict clinical
outcome in tamoxifen-treated ERα-positive breast cancer
patients. This classiﬁer contains genes involved in invasion
(SLIT2 and RECK), anti-inﬂammatory response (TGFBR4,
PTGER4, C3, and GNG2), and cell cycle regulation [65].
In later studies, this group validated a number of hits by
qPCR and hence demonstrated that EZH2 downregulation
is associated with a favourable outcome [66] and thatInternational Journal of Breast Cancer 7
downregulation of SIAH2, an E3-ubiquitin ligase, would
imply tamoxifen resistance [67]. They also showed that an
extracellular matrix cluster of genes (TIMP3, FN1, LOX, and
SPARC) is associated with tamoxifen resistance [68]. In any
of these studies, it is unclear whether phosphorylation of
the estrogen receptor plays a role in tamoxifen resistance in
these patients. Looking at multiple genes, instead of only
one, could be more informative for treatment outcome.
Therefore, Kok et al. compared three gene classiﬁers [69–71]
for tamoxifen. This comparison indicates that a multigene
approach would improve the prediction of response to
tamoxifen [31].
There is as of yet only one microarray study on
tamoxifen-treated ERα-positive human breast cancers that
addresses a speciﬁc phosphorylation site, S305P, and the
eﬀect on gene expression. A pathway analysis highlighted
s e v e r a lp a t h w a y sb e i n ga ﬀected, including PKA, ERK1/2
MAPK, EGF signaling, CDK regulation, and interferonalpha
signaling [44].
7. Discussion
In total, 19 phosphorylation sites have been identiﬁed in
ERα thus far, as summarized in Figure 1. Phosphorylation
of S167, S118, S282, and Y537 is beneﬁcial for tamoxifen
response according to experimental and, for S167, S118 and
S282, because of reported clinical data. Tamoxifen resistance
is likely to occur when S104/S106 or S305 is phosphorylated.
The contribution of phosphorylation of other target sites
to tamoxifen resistance remains to be determined. Some of
these phosphorylation sites have been shown with FRET
technology to induce a conformational change of ERα,
when exposed to other antiestrogens, such as fulvestrant
and raloxifene [6]. Thereby, they may aﬀect the antagonistic
behaviorofthesecompoundsbutthemolecularmechanisms
remain to be elucidated.
Upstream of ERα,d i ﬀerent kinase pathways are involved.
Dependent on the pathway and the phosphorylation sites
involved, tamoxifen response can be aﬀected either directly
through ERα modiﬁcation or by activation of other signaling
pathways. Phosphorylation of S118 is described as an
example of this: an activated ERK1/2 MAPK pathway phos-
phorylates S118 but possibly induces tamoxifen resistance
through the ERK1/2 MAPK pathway itself, rather than ER
signaling. S118 phosphorylation by the ER-associated CDK7
indicates an activated ER which would imply a beneﬁcial
eﬀect on tamoxifen treatment in patients.
EGFR and cErbB2 can also aﬀect ER signaling. Tamox-
ifen response may be restored by blocking EGFR with
geﬁtinib [3, 72]. In a clinical study, blocking cErbB2 with
trastuzumab restores ERα signaling in ERα-positive tumors
and improves response to the aromatase inhibitor letrozole
[73]. This would suggest a better response to tamoxifen as
well.
It is challenging to extrapolate experimental data from
ER activation to the clinic and vice versa.I nin vitro
studies, it is feasible to examine diﬀerential gene expression
after treatment and compare the proﬁle before and after
treatment, or in absence or presence of phosphorylation.
Translation of this information to the clinic can, however, be
troublesome, since adjuvant tamoxifen treatment is started
after surgical removal of the primary tumor. The in vitro
experiments measure gene expression changes associated
with acquired resistance, whereas investigation of primary
tumors that respond better to treatment highlights genes
whichplayaroleinintrinsicresistancetotamoxifen.Because
primary tumors have not been exposed to tamoxifen,
endocrine treatment cannot be a selective factor for these
resistance markers. They may occur at random during
normal tumor development or may well coincide with other
tumor progression markers. For example, overexpression of
cErbB2 or of EGFR in breast cancer marks worse course of
disease not only in ERα-negative, but also in ERα-positive
t u m o r sa n di sam a r k e rf o rt a m o x i f e nr e s i s t a n c ea sw e l l[ 74].
Phosphorylation of Ser305 is a marker for intrinsic
resistance to tamoxifen. It is not associated with disease pro-
gression in the absence of tamoxifen treatment [44]. It is also
a marker for the choice of treatment, since a combination
of S305-P, S118-P, and overexpression of SRC-1 or cyclin
D1 coactivators dictates resistance to diﬀerent antiestrogens
[14, 15]. Since outgrowth of micrometastases into tamoxifen
resistant tumors occurs over longer periods of time (up to 15
years), extra alterations in the micrometastases outgrowths,
in addition to the S305 phosphorylation status, potentially
inﬂuence tamoxifen resistance. Phosphorylation of Ser305,
however, was still maintained in the few metastases samples
that could be examined [44]. Alternatively, one could
study acquired and intrinsic resistance during neoadjuvant
treatment with antiestrogens, where patients are treated
up to three months prior to the surgical removal of the
primary tumor. Hence, samples can be obtained before and
after treatment for comparison [75]. In another study by
this group, activation of the ERK1/2/MAPK pathway was a
majorfactorassociatedwithacquiredresistancetotamoxifen
[74].
Phosphorylation of S305 has experimentally been linked
to resistance to tamoxifen, because of an altered conforma-
tion of ER, where tamoxifen behaves as an agonist in FRET
and expression reporter assays [15]. In patients, S305P was
associated with alterations in the PKA pathway that result
in stimulation of PKA activity [15, 44]. Also experimental
enhancement of PKA activity in breast tumor cells led to
proliferation of T47D breast tumor cells in the presence of
tamoxifen [15]. It is, however, still possible that S305P is a
marker for tamoxifen resistance without any direct involve-
ment. It could merely mark PKA related events that bypass
the estrogen receptor and hence induce tamoxifen resistance.
The altered orientation of components of the transcription
factor complex and the conformational changes in ERα
strongly suggest, but are no proof of, a direct involvement.
S305-P is, however, one of the few selective markers that
predict resistance to tamoxifen in breast cancer patients.
Deﬁnition of the activation of relevant signaling pathways
in the ERα-positive breast tumors (that constitute the bulk
of human breast cancers) prior to endocrine treatment is
essential for treatment success and will ultimately lead to
personalised treatment of breast cancer patients.8 International Journal of Breast Cancer
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